Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Prevalence and risk factors for long COVID after mild disease: a longitudinal study with a symptomatic control group

View ORCID ProfileAna Beatriz C Cazé, View ORCID ProfileThiago Cerqueira-Silva, Adriele Pinheiro Bomfim, Gisley Lima de Souza, Amanda Canário Andrade Azevedo, Michelle Queiroz Aguiar Brasil, Nara Rúbia Santos, Ricardo Khouri, Jennifer Dan, Antonio Carlos Bandeira, Luciano Pamplona de Goes Cavalcanti, View ORCID ProfileManoel Barral-Netto, Aldina Maria Prado Barral, Cynara Gomes Barbosa, View ORCID ProfileViviane Sampaio Boaventura
doi: https://doi.org/10.1101/2022.09.15.22279958
Ana Beatriz C Cazé
1Universidade Federal da Bahia, Salvador, Bahia, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ana Beatriz C Cazé
Thiago Cerqueira-Silva
2LIB and LEITV Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil
1Universidade Federal da Bahia, Salvador, Bahia, Brazil
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Thiago Cerqueira-Silva
Adriele Pinheiro Bomfim
4Instituto Gonçalo Muniz, Fiocruz, Salvador, Brazil
1Universidade Federal da Bahia, Salvador, Bahia, Brazil
M. Sc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gisley Lima de Souza
6Escola de Medicina e Saúde Pública da Bahia
7Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Canário Andrade Azevedo
8Hospital Santa Izabel, Santa Casa da Bahia, Salvador, Bahia, Brazil
MD, M.Sc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Queiroz Aguiar Brasil
7Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil
10Federal University of Bahia, Salvador, Bahia, Brazil
MD, M. Sc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nara Rúbia Santos
11Departamento de Vigilância em Saúde/Vigilância Epidemiológica, Campo Formoso, Bahia Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricardo Khouri
12Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Clinical and Epidemiological Virology, Belgium
7Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Dan
14Center for Infectious Disease and Vaccine Research, la Jolla Institute for Immunology (LJI)
15Department of Medicine, Division of Infectious Disease and Global Public Health, University of California, San Diego (UCSD), La Jolla, CA 92037, USA
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Carlos Bandeira
16UNI-FTC-Faculdade Tecnologia Ciências Medical School, Bahia
17Central State Laboratory LACEN-Bahia
MD, PhD
Roles: Infectious Diseases Advisor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luciano Pamplona de Goes Cavalcanti
18Universidade Federal do Ceará, Fortaleza, Ceará, Brazil
19Centro Universitario Christus, Fortaleza, Ceará, Brazil
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manoel Barral-Netto
2LIB and LEITV Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil
1Universidade Federal da Bahia, Salvador, Bahia, Brazil
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Manoel Barral-Netto
Aldina Maria Prado Barral
22Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Bahia, Brazil
23Instituto de Investigação em Imunologia, São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynara Gomes Barbosa
24Universidade Federal da Bahia, Salvador, Brazil
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viviane Sampaio Boaventura
2LIB and LEITV Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil
1Universidade Federal da Bahia, Salvador, Bahia, Brazil
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Viviane Sampaio Boaventura
  • For correspondence: vsboaventura{at}gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background There is limited data on the prevalence and risk factors for long COVID, with a shortage of prospective studies with appropriate control groups and adequate sample size. We therefore performed a prospective study to determine the prevalence and risk factors for long COVID.

Methods We recruited patients age ≥ 15 years who were clinically suspected of having acute SARS-CoV-2 infection from September 2020 to April 2021. Nasopharyngeal swabs were collected for RT-PCR 3-5 days post symptom onset. Clinical and sociodemographic characteristics were collected using structured questionnaires from persons positive and negative for SARS-COV-2. Follow-up was performed by telephone interview to assess early outcomes and persistent symptoms. For COVID-19 cases, 5D-3L EuroQol questionnaire was used to assess the impact of symptoms on quality of life.

Results We followed 814 participants (412 COVD-19 positive and 402 COVID-19 negative persons) of whom the majority (741 / 814) had mild symptoms. Both the COVID-19 positive and the COVID-19 negative groups had similar sociodemographic and clinical characteristics, except for the rate of hospitalization (15.8% vs 1.5%, respectively). One month after disease onset, 122 (29.6%) individuals reported residual symptoms in the COVID-19 positive group or the long COVID group versus 24 (6%) individuals in the COVID-19 negative group. In the long COVID group, fatigue, olfactory disorder, and myalgia were the most frequent symptoms which occurred in the acute phase. Compared to recovered patients, female sex, older age and having > 5 symptoms during the acute phase were risk factors for long COVID. Quality of life was evaluated in 102 out of 122 cases of long COVID with 57 (55.9%) reporting an impact in at least one dimension of the EuroQol 5D-3L questionnaire.

Conclusion In this prospective study consisting predominantly of patients with mild disease, the persistence of symptoms after acute disease was highly associated with long COVID-19 (29.6% vs 6% of COVID negative group). The risk factors for long COVID were older age, female sex, and polysymptomatic acute disease.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Funding: This study was supported by MCTI/CNPq/FNDCT/MS/SCTIE/Decit (no. 07/2020) MB-N, AB and VSB are research fellows from CNPq, the Brazilian National Research Council. T.C-S. is a PhD student at the Post-Graduation Program in Health Sciences-UFBA, which is supported by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brasil, finance code 001.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval and consent to participate: Informed consent was obtained from all participants. The Ethics in Research Committee of the Goncalo Moniz Research Center approved this study (approval no. 4.315.319/202).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ana.caze{at}ufba.br

  • csilvathiago{at}hotmail.com

  • adrielepbomfim{at}gmail.com

  • gisleysouza19.1{at}bahiana.edu.br

  • amandacanario{at}gmail.com

  • michelleqas{at}gmail.com

  • narabusiness{at}hotmail.com

  • ricardo_khouri{at}hotmail.com

  • jdan{at}ucsd.edu

  • antoniobandeira{at}gmail.com

  • pamplona.luciano{at}gmail.com

  • manoel.barral{at}fiocruz.br

  • aldina.barral{at}fiocruz.br

  • cynara.barbosa{at}gmail.com

  • vsboaventura{at}gmail.com

  • Authors revised 1. Ana Beatriz C Caze 15. Viviane Sampaio Boaventura

Data Availability

Availability of data and materials: The dataset generated and/or analyzed during the current study are not publicly available due to legal and ethical restrictions. Dataset are available upon request.

  • LIST OF ABBREVIATIONS

    STROBE
    Strengthening the Reporting of Observational Studies in Epidemiology
    RT-PCR
    Reverse Transcriptase Polymerase Chain Reaction
    REDCap
    Research Electronic Data Capture software
    IGM/FIOCRUZ
    Gonçalo Moniz Institute
    ICU
    Intensive Care Unit
    SD
    Standard Deviation
    IQR
    Interquartile Range
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted September 22, 2022.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Prevalence and risk factors for long COVID after mild disease: a longitudinal study with a symptomatic control group
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Prevalence and risk factors for long COVID after mild disease: a longitudinal study with a symptomatic control group
    Ana Beatriz C Cazé, Thiago Cerqueira-Silva, Adriele Pinheiro Bomfim, Gisley Lima de Souza, Amanda Canário Andrade Azevedo, Michelle Queiroz Aguiar Brasil, Nara Rúbia Santos, Ricardo Khouri, Jennifer Dan, Antonio Carlos Bandeira, Luciano Pamplona de Goes Cavalcanti, Manoel Barral-Netto, Aldina Maria Prado Barral, Cynara Gomes Barbosa, Viviane Sampaio Boaventura
    medRxiv 2022.09.15.22279958; doi: https://doi.org/10.1101/2022.09.15.22279958
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Prevalence and risk factors for long COVID after mild disease: a longitudinal study with a symptomatic control group
    Ana Beatriz C Cazé, Thiago Cerqueira-Silva, Adriele Pinheiro Bomfim, Gisley Lima de Souza, Amanda Canário Andrade Azevedo, Michelle Queiroz Aguiar Brasil, Nara Rúbia Santos, Ricardo Khouri, Jennifer Dan, Antonio Carlos Bandeira, Luciano Pamplona de Goes Cavalcanti, Manoel Barral-Netto, Aldina Maria Prado Barral, Cynara Gomes Barbosa, Viviane Sampaio Boaventura
    medRxiv 2022.09.15.22279958; doi: https://doi.org/10.1101/2022.09.15.22279958

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (349)
    • Allergy and Immunology (668)
    • Allergy and Immunology (668)
    • Anesthesia (181)
    • Cardiovascular Medicine (2648)
    • Dentistry and Oral Medicine (316)
    • Dermatology (223)
    • Emergency Medicine (399)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
    • Epidemiology (12228)
    • Forensic Medicine (10)
    • Gastroenterology (759)
    • Genetic and Genomic Medicine (4103)
    • Geriatric Medicine (387)
    • Health Economics (680)
    • Health Informatics (2657)
    • Health Policy (1005)
    • Health Systems and Quality Improvement (985)
    • Hematology (363)
    • HIV/AIDS (851)
    • Infectious Diseases (except HIV/AIDS) (13695)
    • Intensive Care and Critical Care Medicine (797)
    • Medical Education (399)
    • Medical Ethics (109)
    • Nephrology (436)
    • Neurology (3882)
    • Nursing (209)
    • Nutrition (577)
    • Obstetrics and Gynecology (739)
    • Occupational and Environmental Health (695)
    • Oncology (2030)
    • Ophthalmology (585)
    • Orthopedics (240)
    • Otolaryngology (306)
    • Pain Medicine (250)
    • Palliative Medicine (75)
    • Pathology (473)
    • Pediatrics (1115)
    • Pharmacology and Therapeutics (466)
    • Primary Care Research (452)
    • Psychiatry and Clinical Psychology (3432)
    • Public and Global Health (6527)
    • Radiology and Imaging (1403)
    • Rehabilitation Medicine and Physical Therapy (814)
    • Respiratory Medicine (871)
    • Rheumatology (409)
    • Sexual and Reproductive Health (410)
    • Sports Medicine (342)
    • Surgery (448)
    • Toxicology (53)
    • Transplantation (185)
    • Urology (165)